Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
Safety and Efficacy of Human Autologous Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
Sponsor: Air Force Military Medical University, China
This PHASE1/PHASE2 trial investigates End Stage Liver Disease and Liver Cirrhosis and is currently ongoing. Air Force Military Medical University, China leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Dec 2022 — Oct 2023 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 3 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Air Force Military Medical University, China
- Chinese Academy of Medical Sciences
- Eastern Hepatobiliary Surgery Hospital
- Fudan University
- The Second Affiliated Hospital of Chongqing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .